This is a multicenter, randomized, double-blind, controlled trial to evaluate the efficacy and safety of an enhanced strategy of allergen-specific immunotherapy (ITIT) in the treatment of allergic rhinitis. By recording the changes in CSMS from baseline to post-treatment in the subjects and the incidence of adverse reactions after treatment, the differences in efficacy and safety between the patients who received the basic three doses and those who received booster injections were compared. Furthermore, the impact of different booster strategies on long-term efficacy was compared to optimize the injection strategy. At the same time, the influence of different administration procedures on the immune response was evaluated.

Inclusion Criteria:

1. Voluntary signing of the informed consent form
2. Commitment to abide by the research procedures and cooperate throughout the implementation of the research
3. Diagnosis conforms to the ARIA guidelines. The basis for the diagnosis is as follows: a. Symptoms: Paroxysmal sneezing, clear nasal discharge, nasal itching, and nasal congestion occur for 2 or more times, with symptoms persisting or accumulating for more than 1 hour each day, accompanied by tearing, eye itching, and eye redness and other ocular symptoms; b. Signs: Commonly, the nasal mucosa is pale and edematous, and nasal watery secretions are present; c. Allergen testing: Positive results for dust mite allergens SPT and/or serum-specific IgE, or positive nasal challenge test, requiring Der p and Der f to be positive (SPT results of ++ or higher, serum sIgE ≥ 2 grades), and other allergens in the allergen test to be negative
4. History of allergic rhinitis caused by atopic dust mite allergens
5. Infertile women must ensure they do not become pregnant during the treatment period
6. Age must be between 5 and 60 years old

Exclusion Criteria:

1. Allergic to the excipients of Arrogel (aluminum hydroxide) or the rescue medication epinephrine
2. Suffering from respiratory system diseases other than stable asthma
3. Pulmonary dysfunction (NYHA grade II or above, or FeV1 < 70%) or having irreversible pathological changes in the reactive organs such as emphysema or bronchiectasis
4. Severe acute or chronic diseases (including malignant diseases), inflammation and fever
5. Multiple sclerosis
6. Immune system diseases (autoimmune diseases, immune diseases caused by antigen-antibody complexes, immune deficiencies, etc.)
7. Active pulmonary tuberculosis
8. Severe mental disorders
9. Obvious cardiac dysfunction
10. Patients who have received immunotherapy within the last 1 years (subcutaneous injection or sublingual administration of allergen-specific immunotherapy, etc.)
11. Patients who used experimental drugs or participated in other clinical studies within 30 days before treatment
12. Patients who received IgE monoclonal antibody (mAb) treatment in the past 4 months
13. Patients taking beta-blockers
14. Patients who have insufficient understanding of the trial
15. Patients whose age is not between 5 years old and 65 years old
16. Patients who are pregnant or breastfeeding during the study period, or have plans to get pregnant
17. Patients who cannot undergo tonsil injection due to acute or chronic tonsillitis, small tonsils, previous tonsillectomy, overly sensitive pharyngeal reflex and inability to cooperate with treatment
18. Patients with aphthous stomatitis

Two years after the completion of the trial, data will be published on the EDC (http://edc.eplat.com.cn/).

Two years after the completion of the trial

Upon approval of the request, access to the de-identified individual patient-level data will be provided. Before accessing the requested information, a data sharing agreement (a non-negotiable contract for data visitors) must be signed.